세계의 폐기종 치료 시장 : 유형별, 치료법별, 환자 유형별, 케어 환경별, 투여 경로별 예측(2025-2030년)

The Emphysema Treatment Market was valued at USD 6.40 billion in 2023, expected to reach USD 6.83 billion in 2024, and is projected to grow at a CAGR of 6.98%, to USD 10.27 billion by 2030.

The scope and definition of the emphysema treatment market encompass a range of medical interventions aimed at managing this chronic, irreversible lung condition, primarily characterized by damaged air sacs and obstructed airflow. Necessity arises as emphysema significantly impairs quality of life, demanding treatments that alleviate symptoms and enhance respiratory function. Applications involve both pharmacological approaches, such as bronchodilators and corticosteroids, and surgical interventions, like lung volume reduction surgery. The end-use scope includes hospitals, clinics, and home healthcare settings. Key growth drivers include an increasing prevalence of chronic obstructive pulmonary disease (COPD) due to aging populations and rising pollution levels, alongside advances in drug development and increasing patient preference for minimally invasive procedures. However, potential growth opportunities lie in expanding healthcare infrastructure in emerging markets and the development of novel therapies, such as regenerative medicines or personalized treatment plans bolstered by AI technologies. Addressing market limitations, challenges primarily stem from stringent regulatory requirements, high costs associated with advanced treatment modalities, and the inherent complexities of conducting clinical trials for respiratory diseases. Economic instability in certain regions could also impede market expansion. Innovative research areas include the development of wearable technology to monitor respiratory health, advances in telemedicine to facilitate remote patient management, and biomarker discovery to enable earlier diagnosis and tailored therapies. The market is dynamic, with a significant focus on technological advancements and a shift towards holistic and patient-centric care models. Companies aiming for business growth should invest in R&D to mitigate challenges and capitalize on emerging opportunities. Collaborations between pharmaceutical firms, healthcare providers, and technology companies could accelerate innovation, leading to better market penetration and improved patient outcomes. Emphasizing cost-effective and accessible treatment options will be crucial as the market continues to expand globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Emphysema Treatment Market

The Emphysema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of smoking and rising pollution levels contributing to higher instances of emphysema
  • Advancements in diagnostic techniques and technologies facilitating early detection and treatment of emphysema
  • Growing geriatric population and higher susceptibility to respiratory diseases among the elderly
  • Rising healthcare expenditure and government initiatives supporting advanced treatment options for emphysema
• Market Restraints
  • Stringent regulatory approvals process for new emphysema treatment drugs and devices causes delays in market entry
  • Low awareness and diagnosis rates of emphysema in rural areas hinder market growth
• Market Opportunities
  • Increasing preference for minimally invasive surgical treatments for emphysema management
  • Growing demand for advanced drug delivery systems for targeted emphysema treatment
  • Rising awareness and screening programs for early detection of emphysema
• Market Challenges
  • Regulatory hurdles and long approval times for new emphysema treatment therapies entering the market
  • Low patient adherence to prescribed treatment regimens due to complicated administration requirements

Porter's Five Forces: A Strategic Tool for Navigating the Emphysema Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Emphysema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Emphysema Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Emphysema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Emphysema Treatment Market

A detailed market share analysis in the Emphysema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Emphysema Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Emphysema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Emphysema Treatment Market

A strategic analysis of the Emphysema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Emphysema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Grifols S.A., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Emphysema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Inhalation Drugs, Intravenous Drugs, and Oral Drugs. The Inhalation Drugs is further studied across Anticholinergics, Long-acting Beta-agonists (LABAs), and Short-acting Beta-agonists (SABAs). The Oral Drugs is further studied across Corticosteroids and Phosphodiesterase-4 inhibitors (PDE4 Inhibitors).
• Based on Treatment, market is studied across Medications, Surgeries, and Therapies. The Medications is further studied across Bronchodilators and Steroids. The Surgeries is further studied across Lung Transplant and Lung Volume Reduction Surgery. The Therapies is further studied across Oxygen Therapy and Pulmonary Rehabilitation.
• Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
• Based on Care Settings, market is studied across Clinics, Home Care, and Hospitals.
• Based on Route of Administration, market is studied across Inhalation, Oral, and Parenteral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of smoking and rising pollution levels contributing to higher instances of emphysema
    • 5.1.1.2. Advancements in diagnostic techniques and technologies facilitating early detection and treatment of emphysema
    • 5.1.1.3. Growing geriatric population and higher susceptibility to respiratory diseases among the elderly
    • 5.1.1.4. Rising healthcare expenditure and government initiatives supporting advanced treatment options for emphysema
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory approvals process for new emphysema treatment drugs and devices causes delays in market entry
    • 5.1.2.2. Low awareness and diagnosis rates of emphysema in rural areas hinder market growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing preference for minimally invasive surgical treatments for emphysema management
    • 5.1.3.2. Growing demand for advanced drug delivery systems for targeted emphysema treatment
    • 5.1.3.3. Rising awareness and screening programs for early detection of emphysema
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and long approval times for new emphysema treatment therapies entering the market
    • 5.1.4.2. Low patient adherence to prescribed treatment regimens due to complicated administration requirements
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Emphysema Treatment Market, by Type

• 6.1. Introduction
• 6.2. Inhalation Drugs
  • 6.2.1. Anticholinergics
  • 6.2.2. Long-acting Beta-agonists (LABAs)
  • 6.2.3. Short-acting Beta-agonists (SABAs)
• 6.3. Intravenous Drugs
• 6.4. Oral Drugs
  • 6.4.1. Corticosteroids
  • 6.4.2. Phosphodiesterase-4 inhibitors (PDE4 Inhibitors)

7. Emphysema Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Medications
  • 7.2.1. Bronchodilators
  • 7.2.2. Steroids
• 7.3. Surgeries
  • 7.3.1. Lung Transplant
  • 7.3.2. Lung Volume Reduction Surgery
• 7.4. Therapies
  • 7.4.1. Oxygen Therapy
  • 7.4.2. Pulmonary Rehabilitation

8. Emphysema Treatment Market, by Patient Type

• 8.1. Introduction
• 8.2. Adult
• 8.3. Geriatric
• 8.4. Pediatric

9. Emphysema Treatment Market, by Care Settings

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Home Care
• 9.4. Hospitals

10. Emphysema Treatment Market, by Route of Administration

• 10.1. Introduction
• 10.2. Inhalation
• 10.3. Oral
• 10.4. Parenteral

11. Americas Emphysema Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Emphysema Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Emphysema Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca plc
• 3. Bayer AG
• 4. Boehringer Ingelheim International GmbH
• 5. Chiesi Farmaceutici S.p.A.
• 6. Cipla Limited
• 7. CSL Limited
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline plc
• 11. Grifols S.A.
• 12. Merck & Co., Inc.
• 13. Mylan N.V.
• 14. Novartis International AG
• 15. Pfizer Inc.
• 16. Sanofi S.A.
• 17. Sumitomo Dainippon Pharma Co., Ltd.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.